32 results about "Polycythemia vera" patented technology

The invention relates to a novel medicine for treating leukemia and a preparation method thereof and belongs to the technical field of traditional Chinese medicines. The medicine is prepared into different preparations by the conventional method in the following steps: by taking taxus chinensis, sculellaria barbata, oldenlandia diffusa, trigone, curcuma zedoary and silkworm bombycis as main materials and cleavers, American ginseng, prismatomeria tetrandra, isatis roots, tuber fleeceflower stems, Tupistra fimbriata Hand.Mazz., fructus corni, lucid ganoderma, human placenta, ligusticum wallichii and turtle shells as auxiliary materials, dosing; drying; respectively grinding fine powder; uniformly mixing; and then steaming and basking for three times. As taxus chinensis contains the No.1 anti-cancer drug in world: paclitaxel and the auxiliary materials assist, growth and development of cancer cells can be controlled, the anticancer ability of human body is boosted, and meanwhile, cyclic and metabolic functions of the human body can be further enhanced, so that viruses accumulated in the human body are eliminated outside by diuresis and defecation so as to realize the effect of treating leukemia. According to clinical trails, the total effective rate is over 90%. The medicine has the best curative effect on acute myelocytic leukemia, myelodysplastic syndromes and graft-versus-host disease, the second effect on polycythemia vera and chronic myelognous leukia, and then acute promyelocytic leukemia.

The invention discloses a TCM (traditional Chinese medicine) preparation for treating polycythemia vera and a preparing method thereof. The TCM preparation comprises, according to a certain weight ratio, Chinese thorowax root, bitter orange, Turmeric root-tuber, Szechuan lovage rhizome, root of common peony, dried rehamnnia root, tree peony bark, safflower, root of red-rooted salvia, zedoary rhizome, ground beetle, cape jasmine, Chinese angelica, Chinese gentian root, natural indigo, baical skullcap root, goldthread, white peony root, hairyvein agrimonia herb and bud, mole cricket, leaf of purpleflower holly, Yerbadetajo herb and blackend swallowwort root. The TCM preparation has the effects of soothing liver-qi and reliving stagnation, regulating qi to disperse stasis, removing heat to cool blood, and nourishing yin and generating body fluid; the TCM preparation has the effect of treating polycythemia vera.

The invention discloses a drug combination and application of a preparation of the drug combination to the fields of preparing drugs for treating chronic granulocytic leukemia, polycythemia vera and primary thrombocytosis. The drug combination is formed through compatibility of natural indigo, tree peony bark, fructus forsythiae, hairyvein agrimony and liquorice, and has remarkable effects of treating the chronic granulocytic leukemia, the polycythemia vera and the primary thrombocytosis.

The present invention relates to a pyrrolopyrimidine five-membered azacyclic derivative as a novel JAK kinase inhibitor, and use thereof in a preparation of a pharmaceutical product for preventing and / or treating an indication related to a JAK kinase function. The pyrrolopyrimidine five-membered azacyclic derivative of the invention is an ideal JAK kinase inhibitor with a high potency, and can be used to treat or prevent diseases such as rheumatoid arthritis, polycythemia vera, psoriasis, primary thrombocytosis, myelofibrosis, and the like. The pyrrolopyrimidine five-membered azacyclic derivative has the general formula of formula I

The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.

The application belongs to the field of medical technology, and discloses a new application specifically related to sorafenib, especially the application of sorafenib in the preparation of drugs for treating myeloproliferative tumors. The myeloproliferative neoplasm is polycythemia vera or ruxolitinib-resistant myeloproliferative neoplasm. The use of sorafenib in the treatment of polycythemia vera provides a new treatment approach for the majority of patients with polycythemia vera, and provides more choices for clinicians and patients. For patients with ruxolitinib-resistant myeloproliferative neoplasms, sorafenib can provide patients with continued oral drug therapy and avoid bone marrow transplantation. Sorafenib can be chemically synthesized at a lower cost than biological agents. And it has been approved by FDA and NMPA for clinical treatment. Its side effects are less and milder, the clinical patient tolerance is good, and the patient burden is lighter.

The present invention discloses the signaling pathway involved erythroid repression by iron deficiency. Further disclosed is anon-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.